Glycemic and Inflammatory status of Type2 Diabetes after Antiviral Therapy for HCV

Changes in Glycemic and Inflammatory status of Type2 Diabetes after Antiviral Therapy for HCV Genotype 4 Patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201712002777310

Enrollment

Registered

2017-11-17

Start date

2017-11-25

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatitis C virus HCV Nutritional, Metabolic, Endocrine Diabetes T2

Interventions

groups of treatments ,Sof/DCV/SMV/RBV

groups of treatments,Sof/DCV/SMV/RBV+ matformin

groups of treatments ,Sof/DCV/SMV/RBV+ sulphonylurea + insulin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 100 Patients diagnosed with type 2 diabetes and HCV-GT4 and treated with two direct antiviral agents (DAAs) will be follow up at 1-baseline, 2-after treatment(12 wks) and 3-12 wks after the end of treatments

Exclusion criteria

Exclusion criteria: Patients with other infectious diseases, autoimmune disorders, asthma, eczema, allergies, thyroid diseases, kidney failure, liver decompensation and alcohol abuse will be excluded from the study.

Design outcomes

Primary

Measure	Time frame
The glycemic status (F. glucose, HbA1c, F. insulin, HOMA-IR) was improved after after antiviral treatments	—

Secondary

Measure	Time frame
changes in IL1,6,-17,23 and Gluc T2 gene polymorphism in diabetic patients treated with DAAs.	—

Countries

Egypt

Contacts

Public ContactAdel Men

Faculty of Science, Beni-Suef University

adel_men2020@yahoo.com+21005451764

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026